Novartis eyes $2.9bn MorphoSys buyout to expand oncology pipeline
ImmunotherapyDrug ApprovalPhase 3AcquisitionAccelerated Approval
Preview
Source: Pharmaceutical Technology
Novartis expects to file for FDA approval in H2 2024 for its pelabresib/ruxolitinib combination treatment. Credits: Taljat David/Shutterstock.com
As per the 5 February press release, Novartis will pay approximately $73 per share and will gain cancer therapies pelabresib (CPI-0610) and tulmimetostat (CPI-0209) upon the acquisition’s completion. Tulmimetostat, an enhancer of zeste homolog 1 and 2 (EZH1/EZH2) protein targeting dual inhibitor, is an early-stage therapeutic candidate being evaluated in a Phase I/II study (NCT04104776) for advanced solid tumours and lymphomas.
Pelabresib is a selective, small-molecule bromodomain and extra-terminal domain (BET) inhibitor designed to downregulate signals involved in myelofibrosis disease pathways and promote anti-tumour activity. The drug is currently being trialled in combination with the Janus kinase (JAK) inhibitor ruxolitinib in the second half of the Phase I/II MANIFEST study (NCT02158858) for myelofibrosis and essential thrombocythaemia, as well as the Phase III MANIFEST-2 study (NCT04603495) for myelofibrosis in patients that have not had previous treatments with JAK inhibitorsJAK inhibitors.
Novartis plans to take the combination treatment to the US Food and Drug Administration (FDA) for approval in H2 2024. GlobalData expects pelabresib to bring in $641m in global sales in 2029.
The agreement comes days after Novartis announced that its net income for the full financial year 2023 (FY 2023) increased by 62% to $8.6bn. In addition, the company gained FDA approval in January to commercially manufacture its metastatic castration-resistant prostate cancer (mCRPC) therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) at its new radioligand therapy manufacturing facility in Indianapolis.
See Also:Incyte acquires global rights to MorphoSys’ tafasitamab
Preview
Source: Pharmaceutical Technology
NeoPhore adds $12.2m in Series B extension for immuno-oncology pipeline
Preview
Source: Pharmaceutical Technology
The Planegg, Germany-based biopharma sold worldwide rights for its humanised Fc-modified CD19-targeting immunotherapy tafasitamab to Incyte for a one-time payment of $25m on 5 February. The FDA granted Tafasitamab an accelerated approval in 2020. The drug is sold on the market as Monjuvi for relapsed or refractory diffuse large B-cell lymphoma. GlobalData predicts that tafasitamab will net $487m in global sales in 2029.
GlobalData is the parent company of Pharmaceutical Technology.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.